Analyzing Retractable Technologies (NYSE:RVP) and GBS (NYSE:GBS)

Valuation & Earnings

This table compares Retractable Technologies and GBS”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Retractable Technologies	$38.16 million	0.69	-$7.01 million	($0.29)	-3.03
GBS	N/A	N/A	-$8.31 million	($0.56)	-1.74

Retractable Technologies has higher revenue and earnings than GBS. Retractable Technologies is trading at a lower price-to-earnings ratio than GBS, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Retractable Technologies has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Profitability

This table compares Retractable Technologies and GBS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Retractable Technologies	-41.11%	-17.15%	-9.33%
GBS	N/A	-85.64%	-54.42%

Insider & Institutional Ownership

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 2.8% of GBS shares are owned by institutional investors. 57.1% of Retractable Technologies shares are owned by company insiders. Comparatively, 0.3% of GBS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Retractable Technologies beats GBS on 9 of the 10 factors compared between the two stocks.

About Retractable Technologies

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.

About GBS

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.